Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
19
8
2022
medline:
15
10
2022
entrez:
18
8
2022
Statut:
ppublish
Résumé
Treatment and prophylaxis options for neonatal HIV are limited. This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options. Using maraviroc concentrations from neonates who received either a single dose or multiple doses of 8 mg/kg of maraviroc in the first 6 weeks of life, a population pharmacokinetic model was developed to determine the effects of age, sex, maternal efavirenz exposure and concomitant ARV therapy on maraviroc disposition. The final model was used in Monte Carlo simulations to generate expected exposures with recommended dosing regimens. A total of 396 maraviroc concentrations, collected in the first 4 days of life, at 1 week, at 4 weeks and at 6 weeks, from 44 neonates were included in the analysis. After allometrically scaling for weight, age less than 4 days was associated with a 44% decreased apparent clearance compared with participants 7 days to 6 weeks of life. There were no differences identified in apparent clearance or volume of distribution from ages 7 days to 6 weeks, sex, maternal efavirenz exposure or concomitant nevirapine therapy. Monte Carlo simulations with FDA-approved weight band dosing resulted in the majority of simulated patients (84.3%) achieving an average concentration of ≥75 ng/mL. While maraviroc apparent clearance is decreased in the first few days of life, the current FDA-approved maraviroc weight band dosing provides maraviroc exposures for neonates in the first 6 weeks of life, which were consistent with adult maraviroc exposure range. Maraviroc provides another antiretroviral treatment option for very young infants.
Sections du résumé
BACKGROUND
Treatment and prophylaxis options for neonatal HIV are limited. This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options.
METHODS
Using maraviroc concentrations from neonates who received either a single dose or multiple doses of 8 mg/kg of maraviroc in the first 6 weeks of life, a population pharmacokinetic model was developed to determine the effects of age, sex, maternal efavirenz exposure and concomitant ARV therapy on maraviroc disposition. The final model was used in Monte Carlo simulations to generate expected exposures with recommended dosing regimens.
RESULTS
A total of 396 maraviroc concentrations, collected in the first 4 days of life, at 1 week, at 4 weeks and at 6 weeks, from 44 neonates were included in the analysis. After allometrically scaling for weight, age less than 4 days was associated with a 44% decreased apparent clearance compared with participants 7 days to 6 weeks of life. There were no differences identified in apparent clearance or volume of distribution from ages 7 days to 6 weeks, sex, maternal efavirenz exposure or concomitant nevirapine therapy. Monte Carlo simulations with FDA-approved weight band dosing resulted in the majority of simulated patients (84.3%) achieving an average concentration of ≥75 ng/mL.
CONCLUSIONS
While maraviroc apparent clearance is decreased in the first few days of life, the current FDA-approved maraviroc weight band dosing provides maraviroc exposures for neonates in the first 6 weeks of life, which were consistent with adult maraviroc exposure range. Maraviroc provides another antiretroviral treatment option for very young infants.
Identifiants
pubmed: 35980827
doi: 10.1097/INF.0000000000003665
pii: 00006454-990000000-00156
pmc: PMC9560968
mid: NIHMS1825162
doi:
Substances chimiques
Alkynes
0
Benzoxazines
0
Cyclopropanes
0
Nevirapine
99DK7FVK1H
efavirenz
JE6H2O27P8
Maraviroc
MD6P741W8A
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
885-890Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI068616
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068632
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106716
Pays : United States
Organisme : NICHD NIH HHS
ID : HHSN275201800001I
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
AIDS. 2021 Mar 1;35(3):419-427
pubmed: 33252481
Eur J Biochem. 1997 Jul 15;247(2):625-34
pubmed: 9266706
Br J Clin Pharmacol. 2009 Sep;68(3):355-69
pubmed: 19740392
J Acquir Immune Defic Syndr. 2022 Mar 1;89(3):324-331
pubmed: 34855626
HIV Clin Trials. 2010 May-Jun;11(3):125-32
pubmed: 20736149
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:27-37
pubmed: 18333863
AIDS Res Hum Retroviruses. 2015 Aug;31(8):783-91
pubmed: 25819584
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:76-85
pubmed: 18333869
Int J Infect Dis. 2013 Oct;17(10):e806-10
pubmed: 23764352
AIDS. 2012 Jul 31;26(12):1483-90
pubmed: 22555165
Curr HIV/AIDS Rep. 2018 Oct;15(5):382-387
pubmed: 30159813
AIDS. 2014 Apr 24;28(7):1049-57
pubmed: 24566097
N Engl J Med. 1994 Nov 3;331(18):1173-80
pubmed: 7935654
N Engl J Med. 1991 Apr 11;324(15):1018-25
pubmed: 1672443
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:38-46
pubmed: 18333864
Clin Pharmacol Ther. 1994 Dec;56(6 Pt 1):615-25
pubmed: 7995003
J Infect Dis. 2008 Aug 15;198(4):465-9
pubmed: 18582198
Drug Metab Dispos. 2012 Dec;40(12):2221-30
pubmed: 22923690
J Infect Dis. 1999 Jul;180(1):93-8
pubmed: 10353866
J Pharmacol Exp Ther. 2003 Nov;307(2):573-82
pubmed: 12975492
J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):554-560
pubmed: 28489732